The absence of detectable germline TP53 mutations in a fraction of families with Li-Fraumeni syndrome (LFS) has suggested the involvement of other genes, but this hypothesis remains controversial. The density of Alu repeats within the TP53 gene led us to search genomic rearrangements of TP53 in families without detectable TP53 mutation. To this aim, we adapted the quantitative multiplex PCR of short fluorescent fragments (QMPSF) method to the analysis of the 11 exons of TP53. We analysed 98 families, either fulfilling (six families) or partially meeting (92 families) the criteria for LFS, and in which classical methods had failed to reveal TP53 alterations. We identified, in a large family fulfilling the criteria for LFS, a complete heterozygous deletion of TP53. Additional QMPSF analyses indicated that this deletion, which partially removed the centromeric FLJ10385 locus, covered approximately 45 kb. This deletion was shown to result from a complex rearrangement involving two distinct Alu-mediated recombinations. We conclude that TP53 germline rearrangements occur as rare events, but must be considered in LFS families without detectable point TP53 mutation. Oncogene (2003Oncogene ( ) 22, 840-846. doi:10.1038 Keywords: TP53; Li-Fraumeni syndrome; deletion; PCR The Li-Fraumeni syndrome (LFS) represents one of the most devastating genetic predispositions to cancers and is characterized by a wide spectrum of early-onset malignancies, including bone and soft-tissue sarcomas, brain tumours, adrenocortical tumours, and premenopausal breast cancers (for a review see Varley et al., 1997; Chompret, 2002) . The first definition of LFS was based on stringent criteria (Li et al., 1988) : (i) a proband with a sarcoma diagnosed before age 45, (ii) a firstdegree relative with cancer before age 45, and (iii) another first-or second-degree relative with either a sarcoma diagnosed at any age or any cancer diagnosed under age 45. Looser selection criteria were subsequently proposed by different investigators to define Li-Fraumeni-like (LFL) syndrome: a proband with any childhood tumour or sarcoma, brain tumour or adrenocortical tumour under 45 years, plus a first-or seconddegree relative with a typical LFS tumour at any age and another first-or second-degree relative with any cancer under the age of 60 (Birch et al., 1994a) ; a clustering of two typical LFS tumours in individuals who are first-or second-degree relatives at any age (Eeles, 1995) ; a proband with a characteristic LFS tumour (sarcoma, brain tumour, breast cancer, adrenocortical carcinoma) before 36 years and at least one first-or second-degree relative with a characteristic LFS tumour (other than breast cancer, if the proband had this) before 46 years or a proband with multiple tumours, two of which represent characteristic LFS tumours and the first of which occurred before 36 years, or a proband with adrenocor-
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Germline mutations of the TP53-tumour suppressor gene have been detected in approximately 70 and 20% of the LFS and LFL families, respectively (Varley et al., 1997) . The absence of detectable germline TP53 mutations in some LFS families has suggested the involvement of other genes, but this hypothesis remains controversial. Numerous genes involved in TP53 pathway, apoptosis, or cell cycle control, such as MDM2 (Birch et al., 1994b) , TP63 (Bougeard et al., 2001) , BCL10 (Stone et al., 1999) , CDKN2A (Burt et al., 1999; Portwine et al., 2000) , PTEN (Burt et al., 1999; Brown et al., 2000) , and CHEK1 (Bell et al., 1999; Vahteristo et al., 2001) , have been considered as candidate genes for LFS, but all these studies have provided negative results. Germline mutations of the CHEK2 gene, encoding a kinase able to phosphorylate Cdc25c and TP53, were initially reported in one LFS family and two families suggestive of LFS (Bell et al., 1999) , but two alleged mutations (1422delT and Ile157Thr) were subsequently shown to be, respectively, on a duplicated exon and a polymorphism (Bell et al., 2000; Sodha et al., 2000; Vahteristo et al., 2001) . The third reported mutation (1100delC) found in two other families suggestive of LFS (Vahteristo et al., 2001) has recently been shown to be a low-penetrance allele conferring susceptibility to breast cancer (Meijers-Heijboer et al., 2002; Vahteristo et al., 2002) . The high frequency of the 1100delC allele argues against any major involvement of CHEK2 in LFS.
The alternative hypothesis, which might explain the absence of detectable germline TP53 mutations in some LFS/LFL families, is the existence of alterations, such as genomic rearrangements, which are missed by conventional screening methods. The genomic sequence of TP53 contains a high density (41%) of Alu repeat elements potentially involved in genomic recombination (Mighell et al., 1997) , with two clusters within introns 1 and 9. Only one germline rearrangement of TP53 deleting the entire exon 10 has already been described in an LFS family (Plummer et al., 1994) . A complex Alu-mediated rearrangement deleting exons 2-4 of TP53 was described in a human pancreatic cancer cell line (Slebos et al., 1998) .
In order to determine the frequency of TP53 genomic rearrangements in LFS, we analysed 98 families (Table 1) , 79 meeting the LFS criteria recently proposed by Chompret et al. (2001) and in which sequence analysis had revealed no TP53 point mutation. To this aim, we used quantitative multiplex PCR of short fluorescent fragments (QMPSF), a method based on simultaneous amplification of multiple short sequences under quantitative conditions (Charbonnier et al., 2000 (Charbonnier et al., , 2002 . Briefly, short fragments corresponding to the 11 TP53 exons and an additional fragment corresponding to another gene, used as control, were simultaneously PCR amplified using dye-labelled primers (Table 2) . Among the 98 families, we detected a TP53 rearrangement in one family fulfilling the strict criteria for LFS ( Figure 1 ). This heterozygous deletion removed all exons of TP53 (Figure 2a ). In contrast, fluorescence in situ hybridization (FISH) performed on metaphases derived from lymphocytes of the proband, using a 145 kb long commercial probe encompassing the TP53 gene (LSI p53, from VYSIS), revealed no deletion (data not shown). Within this family, the TP53 deletion was found in four affected subjects and in one unaffected 70-year old male relative, indicating an incomplete penetrance ( Figure 1) .
We then designed new QMPSF primers to examine the extent of the deletion in the TP53 promoter region and in the genomic sequence downstream the polyadenylation site of TP53 (Table 3) . As shown in Figure 2b , these noncoding regions were also deleted. Additional QMPSFs, exploring the telomeric ATP1B2 gene and the centromeric FLJ10385 hypothetical gene, surrounding TP53 (Table 3 , Figure 3 ), revealed that the heterozygous 17p13 deletion detected in the LFS family partially removed FLJ10385 (Figure 2c,d) . To locate the breakpoint, we then performed long-range PCR, using the P1 primer corresponding to exon 8 of FLJ10385 and the P2 primer corresponding to exon 7 of the ATP1B2 gene (Figure 3a) . While the expected size of the normal fragment is approximately 47 kb, an aberrant fragment of approximately 2 kb was detected in the LFS proband (data not shown). Sequence analysis of this junction fragment and alignment with the chromosome 17 working draft sequence (build 29, contig NT_010823, Li et al. (1998). b According to Birch et al. (1994a) . According to Eeles (1995) . All these families had previously been screened for TP53 mutations by DNA sequence analysis and in some cases by cDNA sequence analysis Owing to a 16 bp polymorphism within intron 3. Note. -PCR was performed in a final volume of 25 ml containing 100 ng of genomic DNA. 1 unit of Taq DNA polymerase (Abgene), 1.2 mm of MgCl 2 , 160 mm of dNTPs and 0.4 mm of each pair of primers except 1.2 mm for exons 2-4 and 10. After a denaturation step of 3 min at 951C, the PCR consisted of 22 cycles of 10 s at 951C, 15 s at 511C and 20 s at 721C, followed by a final extension of 7 min at 721C. To improve the superposition of electropherograms derived from DNA samples extracted using different methods, 5 ml of GeneReleaser solution (BioVentures) was added to the PCR. The control amplicon included in the TP53 QMPSF corresponded to exon 3 of MSH2 located on 2p (sense primer 5 0 GGT AAA ACA CAT TCC TTT GG 3 0 , antisense primer 5 0 ATA TGT CAG CTT CCA TTG GT 3 0 , amplicon size: 210 bp). Figure 1 Pedigree of the LFS family presenting a complete TP53 genomic deletion. Filled symbols, affected subjects; open symbols, asymptomatic subjects; oblique line, deceased; arrow, the proband. For each affected subject, the tumour (or site of the tumour) and age of diagnosis are indicated. Numbers within the symbols correspond to the number of relatives. Breast, breast adenocarcinoma; Glio, glioblastoma; K, cancer of unknown origin; LMS, leiomyosarcoma; MS, metastatic sarcoma; Os, osteosarcoma; STS, soft tissue sarcoma. All the tumours have histologically been confirmed. The genotypes of the relatives, who have been tested, are indicated: wt/wt, wild-type genotype; wt/del, heterozygous deletion of the TP53 gene.*, incomplete penetrance in a 70-year-old male; **, phenocopy. The pedigree has been encrypted to protect confidentiality of family members TP53 genomic complete deletion in LFS G Bougeard et al After purification of PCR products, using the Qiagen PCR purification kit, electrophoresis was performed on an automated sequencer (model 377, PE Applied Biosystems, Perkin-Elmer) and data were analysed using the Gene scanner model 672 fluorescent fragment analyser (PE Applied Biosystems, Perkin-Elmer)
TP53 genomic complete deletion in LFS
TP53 genomic complete deletion in LFS G Bougeard et al 0 UTR of exon 7 of ATP1B2, are shown as a light grey box. The AGCT motif present both in FLJ10385 exon 6 and in the TP53-ATP1B2 intergenic sequence, in which the 35.2 kb deletion had occurred, and the short region of complete homology between Alu Sg in the intergenic sequence and Alu Sp in exon 7 of ATP1B2, in which the 9.4 kb deletion had occurred, are both underlined GI:20560291) revealed the occurrence of two distinct recombinations (Figure 3b ): the last 84 bp of FLJ10385 exon 6 were fused to the TP53-ATP1B2 intergenic sequence, removing 35.2 kb of genomic sequence including the entire TP53 gene; moreover, the TP53-ATP1B2 intergenic sequence was fused to the 3 0 UTR of ATP1B2 located within exon 7, deleting 9.4 kb of genomic sequence. Alignment and analysis of the nucleotide sequences, using the RepeatMasker program (http:// repeatmasker.genome.washington.edu), revealed that the first breakpoint, which disrupted FLJ10385 exon 6, was located within an AGCT motif, present both in exon 6 of FLJ10385 and in the TP53-ATP1B2 intergenic sequence. Alu Sq repeats were found 302 and 25 bp from the AGCT motif within FLJ10385 and TP53-ATP1B2 intergenic sequence, respectively. The other recombination had occurred between an Alu Sg and an Alu Sp repeat located within the TP53-ATP1B2 intergenic sequence and in the 3 0 UTR of ATP1B2, respectively, and the breakpoint was within a 16-bp homology region (Figure 3b) . This is to our knowledge the first report of a complete heterozygous germline deletion of TP53. It is interesting to note that this alteration, which results in a complete TP53 haplo-deficiency, was not associated with a more severe phenotype than that observed in families fulfilling the strict LFS criteria. This report also demonstrates that Alu repeats surrounding the TP53 locus are recombinogenic. Although the involvement of Alu repeats in the previously reported genomic deletion of exon 10 (Plummer et al., 1994) has not been demonstrated, the density of Alu sequences within introns 9 and 10 (72 and 31%, respectively) supports this hypothesis. This study shows that germline rearrangements of TP53, which are missed by conventional screening methods, based either on PCR amplification of each exon or on RT-PCR, or by FISH performed with commercially available probes, occur in LFS. Although we cannot exclude that some of the families included in the present study may correspond to nonMendelian aggregation of tumours belonging to the LFS spectrum, rather than to LFS, this report indicates that germline rearrangements occur rarely within TP53, in contrast to other genes involved in genetic predisposition to cancer such as RB or MSH2.
Nevertheless, the presence of TP53 genomic rearrangements should be considered in LFS families without detectable point mutation, especially those fulfilling the strict LFS criteria. Therefore, we conclude that the QMPSF method, which can detect not only heterozygous deletions but also duplications, should be included in the routine diagnosis of LFS.
